
Vonoprazan
Price | Get Latest Price | |
Package | 1kg | 25kg |
Min. Order: | 1kg |
Supply Ability: | 800kg |
Update Time: | 2025-03-04 |
Product Details
Product Name: Vonoprazan | CAS No.: 881681-00-1 |
Min. Order: 1kg | Purity: 0.99 |
Supply Ability: 800kg | Release date: 2025/03/04 |
? ?Vonoprazan (CAS 881681-00-1) | High-Purity Potassium-Competitive Acid Blocker (P-CAB)? ?
?? ?Product Overview?
?Vonoprazan? (CAS 881681-00-1) is a ?potent potassium-competitive acid blocker? (P-CAB) with the molecular formula ?C??H??FN?O?S? and a molecular weight of ?345.39?. This white to off-white crystalline powder (purity ≥98%) is designed for ?acid-related gastrointestinal disorder treatment?, offering rapid and sustained suppression of gastric acid secretion. It reversibly inhibits H+/K+-ATPase in gastric parietal cells, outperforming traditional proton pump inhibitors (PPIs) with faster onset and longer efficacy.
?Key Functions?:
Treats ?gastroesophageal reflux disease (GERD)? and peptic ulcers?.
Enhances ?Helicobacter pylori eradication therapy? outcomes.
Serves as a pharmaceutical intermediate for advanced formulations.
?Target Industries?: Pharmaceutical manufacturing, clinical research, and biotechnology.
? ?Key Advantages?
≥98% HPLC/EP-certified | Acid suppression within 30 minutes | Stable at -20°C, moisture-proof |
Batch-specific COA | Duration up to 24 hours | 24-month shelf life |
?? ?Applications?
?GERD Management?: Oral tablets for chronic acid reflux relief.
?H. pylori Eradication?: Combined with antibiotics for dual therapy.
?Peptic Ulcer Therapy?: Reduces recurrence rates in clinical settings.
?Drug Development?: Intermediate for novel P-CAB formulations.
?? ?Quality Assurance?
?Testing Standards?: Complies with ?USP/EP? pharmacopeial guidelines.
?Analytical Validation?: HPLC, NMR, and LC-MS for identity and impurity profiling.
?Certifications?: ISO 9001 and GMP compliance for pharmaceutical-grade production.
?? ?Market Insights?
The global GERD treatment market is projected to reach ?$6.8 billion by 2030?, driven by rising demand for non-PPI therapies and Asia-Pacific’s dominance in cost-efficient API manufacturing. Vonoprazan is increasingly adopted due to its superior pharmacokinetics and clinical efficacy.
Company Profile Introduction
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$29.00/50mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-18 | |
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-11-15 | |
$0.00/1KG Ton |
VIP3Y
|
Zhuhai Hairuide Bioscience and Technology Co., Ltd
|
2022-10-09 | |
$0.00/1G |
Senova Technology Co. Ltd.
|
2022-05-10 | ||
$0.00/1Kg/Bag |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-10-22 | |
$1.00/1g |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-04-30 | |
$1.00/100g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-20 |
- Since: 2018-06-08
- Address: Biolake.858 high-tech avenue,Wuhan
+86-+undefined-+86 13343427080
sales@biocarchem.com